Introduction
normal range at 8340/mm3. Isotopic measurement of the red cell mass confirmed absolute moderate polycyTacrolimus is a calcineurin inhibitor. It is a potent thaemia. Serum erythropoietin ( Epo) level was immunosuppressive drug which has been approved in increased at 37 mIU/ml (normal [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The kidney, several countries. It is currently indicated for both liver, and spleen sonograms were normal. Allograft prophylaxis and treatment of allograft rejection. and native renal artery Doppler ultrasound images did Metabolism of tacrolimus occurs primarily in the liver not reveal any stenosis. In order to reduce Epo producvia the cytochrome P450-3A4 (CYP3A4) enzyme tion, the angiotensin-converting enzyme inhibitor system. There are many potential drugs interacting (ACEi) enalapril was added to the treatment, but with tacrolimus which should be used with caution, without success. During a period of 3 months, eight particularly in patients who are concurrently taking phlebotomy sessions (300-400 ml/session) were used CYP3A4 inhibitors or inducers [1, 2] . We report herein to control Hb levels. In October 1998, in order to the first case of tacrolimus and theophylline interaction reduce the need for phlebotomies, theophylline in a renal transplant recipient.
(600 mg/day) was added to the ACEi. After 1 month, serum creatinine and tacrolimus TBC rose to 145 mmol/l and 16 ng/ml respectively. Therefore, the Case theophylline dose was reduced to 300 mg/day four times weekly, which led to a significant reduction in In March 1998, a 33-year-old man with end-stage renal the number of necessary phlebotomy sessions. Only disease due to diabetic nephropathy received a cada-two further phlebotomies were required to keep Hb veric kidney allograft. He had no history of cardiac or and Hct levels within acceptable ranges. One month pulmonary disease. Post-transplantation maintenance later, serum creatinine and tacrolimus TBC increased immunosuppressive therapy included tacrolimus further to 175 mmol/l and 48.5 ng/ml respectively (7 mg/d ), azathioprine (75 mg/d ) and prednisone ( Figure 1 ). Although theophylline serum concentra-(7.5 mg/d ). The patient was also receiving insulin with tions remained low (2 and 6.7 mg/l; normal range no other drugs. The post-operative course was unevent-10-15), this drug was discontinued and both renal ful with no rejection episodes and no hypertension. At function and tacrolimus TBC rapidly returned to discharge, the serum creatinine was 110 mmol/l. White normal values. ACEi was replaced without further blood count ( WBC ), haemoglobin (Hb) and haemato-success by losartan, a specific angiotensin-II (A-II ) crit (Hct) values were 3870/mm3, 12.3 g/dl and 43% receptor antagonist (25 mg/d). respectively. The tacrolimus trough blood concentraTherefore, the patient was readmitted for reintroduction (tacrolimus TBC ) assayed using a microparticle tion of theophylline at a lower dose. At this time, the enzyme immunoassay and IMx autoanalyser, was pharmacokinetics of tacrolimus were assessed. The patient was kept on the same doses of maintenance anti-rejection treatment, insulin therapy and losartan. Various causes have been suggested to explain this phenomenon [4] [5] [6] [7] . It is thought to be a self-limiting process that requires appropriate management, including supportive therapy (phlebotomy) and a pharmacological approach in order to block Epo secretion. Options in this regard have included ACEi, specific A-II receptor antagonists and theophylline [8] [9] [10] . A number of clinically relevant interactions between calcineurin inhibitors and co-administered drugs have been reported [1, 2, 11] . However, to the best of our knowledge, no case of calcineurin inhibitor-theophylline interaction has been previously reported.
It is well known that CYP3A4 is primarily responsible for tacrolimus liver biotransformation. Substances known to inhibit CYP3A4 may decrease tacrolimus metabolism and thereby increase its blood concentra- tions. Aminophylline is rapidly hydrolysed during its first pass, which leads to the formation of the active compound theophylline [12] . CYP1A2 is considered assessed at day 0 (before theophylline administration) and after 4 days of theophylline administration (day to be the most important enzyme involved in theophylline liver metabolism [13] , while CYP3A4 has a minor 4) respectively. Blood samples were taken at days 0 and 4, pre-and post-tacrolimus intake, and every 2 h role in theophylline metabolism. It is therefore surprising that the tacrolimus-theophylline interaction for 10 h post-tacrolimus initiation. Theophylline coadministration led to an increase in the tacrolimus area appears in this matter.
In vitro, theophylline concentration, at 10 times under the curve from 0 to 10 h (AUC 0-10 h: 25 vs 142 ng/h/ml ). While the maximum concentration molar excess of tacrolimus, barely inhibits (by 5%) CYP3A4 tacrolimus metabolism [14] . In the present increased from 19.3 to 37.4 ng/ml ( Figure 2 ), no significant changes in renal function were noted. case, at the time of interaction and despite low-dose theophylline, the calculated theophylline-tacrolimus Theophylline serum concentration determined by HPLC, before, or during tacrolimus administration, concentration molar ratio was about 750. If the above in vitro findings are taken into consideration, this were at low values. The peak theophylline concentration was 4.3 mg/l, occurring at 2 h post-theophylline interaction may be explained by the very high ratio of theophylline/tacrolimus molar concentrations, as in administration. A few days after discharge, theophylline was withheld because of gastric discomfort. fact expected when these two drugs are used concomitantly. Erythrocytosis is currently controlled with routine phlebotomy sessions and losartan.
Conclusions Discussion
Theophylline interacts with tacrolimus liver metabolPost-renal transplant erythrocytosis is a well-known ism by inhibiting the CYP3A4. Although in the present complication, which usually occurs within the first 2 case a low theophylline dose led to tacrolimus AUC years after surgery [3, 4] . About 10-20% of kidney increase, renal function remained stable. Therefore low transplant patients develop this complication [5] .
dose theophylline can be used in transplant patients with erythrocytosis, provided that tacrolimus concentrations are closely monitored.
